drugset / Trial / NCT05322473
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Timeline
- Start
- 2022-04-25
- Primary completion
- 2023-05-09
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | — | — |
| Subject | M1095 | Protein / enzyme biologic | — | Subcutaneous |